Immuneed

Immuneed, founded from research at Uppsala University, focuses on developing innovative prostate cancer vaccines that harness the body's immune system to target tumor cells. As a contract research organization, Immuneed specializes in therapeutic cancer vaccine research, offering services in immunotoxicology and immunophenotyping through human whole-blood assays. The company emphasizes the use of monoclonal antibodies, aiming to provide medical institutions and health organizations with advanced, patent-pending solutions that improve peptide uptake and enhance cellular immune activation.